Total stock-based compensation expense $4,371 $27,750
As of As of
December 31, December 31,
Cash & cash equivalents $246,492 $231,975
Marketable securities - current and
long-term 304,543 682,692
Accounts receivable 496,636 511,136
Other receivables 86,048 67,462
Inventory 501,207 426,270
Accounts payable & accrued liabilities 442,193 408,763
Working capital 970,854 876,106
Total assets 4,761,627 4,961,862
Total debt 2,079,757 2,677,668
Shareholders' equity 1,866,321 1,465,228
Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA
To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the year and quarter ended December 31, 2007, and (2) the calculation of EBITDA for each period presented.
Adjusted earnings per share and EBITDA are non-GAAP financial measures.
The Company is providing this information, however, because it believes
that such information is useful to both management and investors in that it
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved